NCT06643910 - A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL

Single drug group A

9x10\^10 BST08 cells, Intravenous infusion，3 subject is planned to be enrolled

BIOLOGICAL

Combined treatment group B

9x10\^10 BST08 cells+ Pembrolizumab Injection，200mg，Q3W, Intravenous infusion，6subject is planned to be enrolled

Trial Locations (1)

Yuqing Li, Shenzhen

All Listed Sponsors

collaborator

South China Hospital of Shenzhen University

UNKNOWN

lead

BioSyngen Pte Ltd

INDUSTRY